This panel will delve into the marked differences in production requirements and access to medicinal cannabis in Europe and the United States. We will explore the various perspectives and options available in both contexts, seeking the optimal approach to provide quality care to those who need it most: the patients.

Nearly half of the states in the U.S. have now passed adult-use cannabis legalization measures, with many of them currently being home to thriving adult-use industries. Nearly every state in the U.S. has a legal medical cannabis industry operating in some form. Comparatively, Europe’s legal cannabis industry is still young and possesses more potential for entrepreneurs and investors who want to get in on the continent’s ground floor. A panel of leading global cannabis experts will discuss what opportunities to look for in Europe, how Europe’s industry compares to the United States, and what market entry requisites U.S. companies need to consider when exploring expansion efforts involving European Union member nations.

The field of cannabinoid research is evolving at a greater rate than ever before, with new discoveries being made in labs and in the field about the potential therapeutic benefits of these compounds. The focus of cannabinoid research, the methods of research, and the motivating factors driving cannabis research look much different today than they did just a handful of years ago. Panelists will discuss recent scientific breakthroughs, emerging research methodology, and what people can expect from the field of cannabis research in the coming years.